Sonoma Pharmaceuticals logo

Sonoma PharmaceuticalsNASDAQ: SNOA

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 January 2007

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.75 M
-84%vs. 3y high
7%vs. sector
-vs. 3y high
-vs. sector
-66%vs. 3y high
30%vs. sector
-82%vs. 3y high
6%vs. sector

Price

after hours | 24 min ago
$2.68-$0.31(-10.37%)

Dividend

No data over the past 3 years
$3.39 M$3.98 M
$3.39 M-$1.14 M

Analysts recommendations

Institutional Ownership

SNOA Latest News

Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
accesswire.com31 October 2024 Sentiment: POSITIVE

BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2024 in Düsseldorf, Germany November 11-14, 2024. MEDICA is considered the largest and most prestigious medical trade fair in the world, expected to attract over 120,000 visitors from more than 70 countries and over 5,300 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare IT.

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock
accesswire.com28 August 2024 Sentiment: NEUTRAL

BOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the timing for a 1-for-20 reverse split of its outstanding common stock which will be effected on August 29, 2024 at 5:00 pm EDT. Sonoma common stock will begin trading on The Nasdaq Capital Market on a 1-for-20 adjusted basis when the market opens on August 30, 2024.

Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine
accesswire.com09 July 2024 Sentiment: POSITIVE

BOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announces it is celebrating its 20th anniversary of selling wound care products in Europe. Sonoma is also proud to announce that it is expanding its distributor base in Europe by adding a new partnership with Smart Healthcare Company (SHC) s.r.o.

Sonoma Pharmaceuticals (SNOA) Shows Fast-paced Momentum But Is Still a Bargain Stock
zacks.com28 June 2024 Sentiment: POSITIVE

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results
accesswire.com17 June 2024 Sentiment: POSITIVE

Revenues increased 14% in Q4 2024 compared to Q4 2023 Gross profit margin improved 3% in FY 2024 compared to FY 2023 Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to FY 2023 BOULDER, CO / ACCESSWIRE / June 17, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2024 and the fourth quarter ended March 31, 2024. "We are pleased to report continued product-related growth and reduced cash burn in both our fourth quarter and fiscal year 2024 results.

Sonoma Pharmaceuticals Shares Soar 44% After Introducing New Product
Investopedia09 June 2023 Sentiment: POSITIVE

Sonoma Pharmaceuticals shares jumped 44% on Friday after the company unveiled a product that could replace IV bags for some surgeries.

What type of business is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

What sector is Sonoma Pharmaceuticals in?

Sonoma Pharmaceuticals is in the Healthcare sector

What industry is Sonoma Pharmaceuticals in?

Sonoma Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Sonoma Pharmaceuticals from?

Sonoma Pharmaceuticals is headquartered in United States

When did Sonoma Pharmaceuticals go public?

Sonoma Pharmaceuticals initial public offering (IPO) was on 25 January 2007

What is Sonoma Pharmaceuticals website?

https://sonomapharma.com

Is Sonoma Pharmaceuticals in the S&P 500?

No, Sonoma Pharmaceuticals is not included in the S&P 500 index

Is Sonoma Pharmaceuticals in the NASDAQ 100?

No, Sonoma Pharmaceuticals is not included in the NASDAQ 100 index

Is Sonoma Pharmaceuticals in the Dow Jones?

No, Sonoma Pharmaceuticals is not included in the Dow Jones index

When was Sonoma Pharmaceuticals the previous earnings report?

No data

When does Sonoma Pharmaceuticals earnings report?

The next expected earnings date for Sonoma Pharmaceuticals is 13 November 2024